SCHEMBL4470434

SCHEMBL4470434

CCc1cc(O)c(C(C)=O)c(C(C)C)c1OC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.40
PTGES O14684 1/20 0.40
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
CYP3A4 P08684 2/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 2/20 0.37
ALOX12 P18054 2/20 0.37
KDM4E B2RXH2 3/20 0.36
LDHA P00338 1/20 0.36
LDHB P07195 1/20 0.36
AKR1B1 P15121 1/20 0.36
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.35
ABL1 P00519 1/20 0.35
RECQL P46063 1/20 0.35
RIN1 Q13671 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
FFAR1 O14842 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465924 0.81 CYP3A4 (0.41) ALOX5PTGESMEN1KMT2ACYP3A4
SCHEMBL4464395 0.80 CYP3A4 (0.40) ALOX5MEN1KMT2ACYP3A4HPGD
SCHEMBL4475698 0.77 PTGES (0.37) ALOX5PTGESMEN1KMT2ACYP3A4
SCHEMBL27688768 0.73 CYP3A4 (0.37) ALOX5MEN1KMT2ACYP3A4HPGD
SCHEMBL4462555 0.72 KDM4E (0.51) MEN1KMT2ACYP3A4HPGDKDM4E
SCHEMBL4469962 0.70 CYP3A4 (0.39) ALOX5PTGESMEN1KMT2ACYP3A4
SCHEMBL28992427 0.69 CYP3A4 (0.48) MEN1KMT2ACYP3A4KDM4ELDHA
SCHEMBL27708365 0.69 PTGES (0.35) ALOX5PTGESMEN1KMT2ACYP3A4
SCHEMBL27852474 0.67 AKT1 (0.46) ALOX5MEN1KMT2ACYP3A4KDM4E
SCHEMBL3083354 0.67 LMNA (0.47) ALOX5CYP3A4HPGDKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
CN-101115734-A Spiro derivatives as lipoxygenase inhibitors LILLY CO ELI (US) 2008-01-30 CN disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 ALOX5 2/4885PTGES 10/4885MEN1 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.